NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana

Core Insights - NurExone Biologic Inc. is establishing its first U.S. commercial exosome production facility in Indianapolis, Indiana, with an incentive offer of up to US$255,000 [1][2][3] - The Indianapolis facility will serve as Exo-Top's U.S. manufacturing base, producing exosomes for both NurExone's therapeutic pipeline and business-to-business opportunities in regenerative aesthetics [2][4] - Indiana's life sciences sector generates over US$99 billion annually and has attracted more than US$1.5 billion in venture investments since 2019, making it an attractive location for Exo-Top [3][6] Company Overview - NurExone is focused on developing exosome-based regenerative therapies for central nervous system injuries, with its lead product, ExoPTEN, showing strong preclinical data [6] - The company aims to progress towards first-in-human clinical trials and plans to uplist to a major U.S. stock exchange [4][6] - Exo-Top Inc. has been established as a U.S. subsidiary to anchor NurExone's North American growth strategy [6]